IP Library › Granted Patent US 10,835,537
Granted Patent B2
US 10,835,537 · App. 16/821,762 · Granted Nov 17, 2020

Combination therapies for treatment of cancer

Inventors: David J. Bearss (Lehi, UT); Steven L. Warner (Lehi, UT); Adam Siddiqui-Jain (Lehi, UT); Clifford J. Whatcott (Lehi, UT); Wontak Kim (Lehi, UT)
Assignee: Sumitomo Dainippon Pharma Oncology, Inc.
A61K31/519A61K31/445A61K31/4433A61K31/453A61K31/706A61K45/06A61P35/02C07D405/04C07D405/10A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,835,537
App. No.
16/821,762
Granted
Nov 17, 2020
Kind
B2
Abstract

Combination therapies for treatment of cancer are provided. The disclosed methods comprise administration of a cyclin-dependent kinase inhibitor and a DNA methyltransferase inhibitor to a mammal in need thereof.

Claims (6)

1. A method of treating a subject with myelodysplastic syndrome (MDS) comprising treating the subject with a therapeutically effective amount of at least one of decitabine or azacitidine and a therapeutically effective amount of alvocidib.

2. The method of claim 1 comprising treating the subject with a therapeutically effective amount of decitabine and a therapeutically effective amount of alvocidib.

3. The method of claim 1 comprising treating the subject with a therapeutically effective amount azacitidine and a therapeutically effective amount of alvocidib.

4. A method of treating a subject with myelodysplastic syndrome (MDS) comprising administering to the subject with a therapeutically effective amount of at least one of decitabine or azacitidine and a therapeutically effective amount of alvocidib.

5. The method of claim 4 comprising administering to the subject a therapeutically effective amount of decitabine and a therapeutically effective amount of alvocidib.

6. The method of claim 4 comprising administering the subject a therapeutically effective amount azacitidine and a therapeutically effective amount of alvocidib.

Assignments (4)
CHANGE OF NAME Recorded Apr 27, 2022
From: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
To: SUMITOMO PHARMA ONCOLOGY, INC.
Reel/Frame 059809/0557 →
MERGER Recorded Jul 10, 2020
From: TOLERO PHARMACEUTICALS, INC.
To: BOSTON BIOMEDICAL, INC.
Reel/Frame 053181/0114 →
CHANGE OF NAME Recorded Jul 10, 2020
From: BOSTON BIOMEDICAL, INC.
To: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
Reel/Frame 053181/0133 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2020
From: BEARSS, DAVID J.; WARNER, STEVEN L.; SIDDIQUI-JAIN, ADAM; WHATCOTT, CLIFFORD J.; KIM, WONTAK
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 052335/0142 →